Stammdaten
Unternehmen
| Name | Dianthus Therapeutics, Inc. /DE/ |
|---|---|
| Ticker | DNTH |
| CIK | 0001690585 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Dianthus Therapeutics, Inc. /DE/ |
Status
| Zuletzt geprüft | 2026-03-20 22:34:59.662673 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -33,830 | 81.48 | -2,756,468.40 | -179,2% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -15,852 | 80.71 | -1,279,414.92 | -83,2% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -23,465 | 81.75 | -1,918,263.75 | -124,7% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -3,865 | 82.66 | -319,480.90 | -20,8% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -200 | 83.38 | -16,676.00 | -1,1% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -300 | 85.53 | -25,659.00 | -1,7% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -43,505 | 80.69 | -3,510,418.45 | -228,2% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -65,517 | 81.74 | -5,355,359.58 | -348,1% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -12,796 | 82.60 | -1,056,949.60 | -68,7% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -200 | 83.38 | -16,676.00 | -1,1% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -900 | 85.53 | -76,977.00 | -5,0% | |
| 2025-12-04 | Savitz Ryan | Officer, CFO & CBO | Open Market Sale | -20,000 | 45.18 | -903,600.00 | -58,7% | |
| 2025-11-14 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -109,031 | 38.14 | -4,158,442.34 | -270,3% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -26,166 | 35.80 | -936,742.80 | -60,9% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -42,765 | 37.04 | -1,584,015.60 | -103,0% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -18,576 | 37.72 | -700,686.72 | -45,5% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.